128 related articles for article (PubMed ID: 26053275)
1. Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes.
Zhang H; Jing X; Wu X; Hu J; Zhang X; Wang X; Su P; Li W; Zhou G
Anticancer Drugs; 2015 Aug; 26(7):706-15. PubMed ID: 26053275
[TBL] [Abstract][Full Text] [Related]
2. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
Wang YH; Imai Y; Shiseki M; Tanaka J; Motoji T
Leuk Res; 2018 Apr; 67():99-108. PubMed ID: 29482174
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
5. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway.
Zhang H; Zhang X; Wu X; Li W; Su P; Cheng H; Xiang L; Gao P; Zhou G
Cancer Lett; 2012 Oct; 323(1):106-113. PubMed ID: 22484497
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-γ ligands via Wnt signaling pathway.
Liu JJ; Dai XJ; Xu Y; Liu PQ; Zhang Y; Liu XD; Fang ZG; Lin DJ; Xiao RZ; Huang RW; Huang HQ
Cell Biochem Biophys; 2012 Jan; 62(1):19-27. PubMed ID: 21837368
[TBL] [Abstract][Full Text] [Related]
7. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Ma T; Huang C; Zhang L; Lv X; Xu T; Hu T; Li J
Cell Signal; 2013 Dec; 25(12):2693-701. PubMed ID: 24018051
[TBL] [Abstract][Full Text] [Related]
8. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
9. Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Huang C; Ma T; Jiang L; Tang L; Shi T; Zhang S; Zhang L; Zhu P; Li J; Shen A
Phytomedicine; 2018 Apr; 43():37-45. PubMed ID: 29747752
[TBL] [Abstract][Full Text] [Related]
10. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.
Yousefi B; Azimi A; Majidinia M; Shafiei-Irannejad V; Badalzadeh R; Baradaran B; Zarghami N; Samadi N
Tumour Biol; 2017 Oct; 39(10):1010428317716501. PubMed ID: 28978268
[TBL] [Abstract][Full Text] [Related]
11. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells.
Yu ST; Chen TM; Tseng SY; Chen YH
Biochem Biophys Res Commun; 2007 Jun; 358(1):79-84. PubMed ID: 17482571
[TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
[TBL] [Abstract][Full Text] [Related]
14. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
Smith AG; Beaumont KA; Smit DJ; Thurber AE; Cook AL; Boyle GM; Parsons PG; Sturm RA; Muscat GE
Int J Biochem Cell Biol; 2009 Apr; 41(4):844-52. PubMed ID: 18822385
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
16. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition.
Yun UJ; Lee JH; Koo KH; Ye SK; Kim SY; Lee CH; Kim YN
Biochem Pharmacol; 2013 May; 85(10):1441-53. PubMed ID: 23473805
[TBL] [Abstract][Full Text] [Related]
17. MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.
Li L; Jiang AC; Dong P; Wang H; Xu W; Xu C
Ann Surg Oncol; 2009 May; 16(5):1421-8. PubMed ID: 19247716
[TBL] [Abstract][Full Text] [Related]
18. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
Hille S; Rein DT; Riffelmann M; Neumann R; Sartorius J; Pfützner A; Kurbacher CM; Schöndorf T; Breidenbach M
Anticancer Drugs; 2006 Oct; 17(9):1041-4. PubMed ID: 17001177
[TBL] [Abstract][Full Text] [Related]
19. Microvesicles mediate transfer of P-glycoprotein to paclitaxel-sensitive A2780 human ovarian cancer cells, conferring paclitaxel-resistance.
Zhang FF; Zhu YF; Zhao QN; Yang DT; Dong YP; Jiang L; Xing WX; Li XY; Xing H; Shi M; Chen Y; Bruce IC; Jin J; Ma X
Eur J Pharmacol; 2014 Sep; 738():83-90. PubMed ID: 24877693
[TBL] [Abstract][Full Text] [Related]
20. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]